These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35241721)

  • 21. Comparison of hypofractionation and standard fractionation for post-prostatectomy salvage radiotherapy in patients with persistent PSA: single institution experience.
    Murgic J; Jaksic B; Prpic M; Kust D; Bahl A; Budanec M; Prgomet Secan A; Franco P; Kruljac I; Spajic B; Babic N; Kruslin B; Zovak M; Zubizarreta E; Rosenblatt E; Fröbe A
    Radiat Oncol; 2021 May; 16(1):88. PubMed ID: 33980277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibiting the aurora B kinase potently suppresses repopulation during fractionated irradiation of human lung cancer cell lines.
    Sak A; Stuschke M; Groneberg M; Kübler D; Pöttgen C; Eberhardt WE
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):492-9. PubMed ID: 22381900
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MicroRNA-145 Modulates Tumor Sensitivity to Radiation in Prostate Cancer.
    Gong P; Zhang T; He D; Hsieh JT
    Radiat Res; 2015 Dec; 184(6):630-8. PubMed ID: 26632856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term clinical outcomes after 12-fractionated carbon-ion radiotherapy for localized prostate cancer.
    Sato H; Kasuya G; Ishikawa H; Nomoto A; Ono T; Nakajima M; Isozaki Y; Yamamoto N; Iwai Y; Nemoto K; Ichikawa T; Tsuji H;
    Cancer Sci; 2021 Sep; 112(9):3598-3606. PubMed ID: 34107139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
    Wilkins A; Mossop H; Syndikus I; Khoo V; Bloomfield D; Parker C; Logue J; Scrase C; Patterson H; Birtle A; Staffurth J; Malik Z; Panades M; Eswar C; Graham J; Russell M; Kirkbride P; O'Sullivan JM; Gao A; Cruickshank C; Griffin C; Dearnaley D; Hall E
    Lancet Oncol; 2015 Dec; 16(16):1605-16. PubMed ID: 26522334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation.
    Rudner J; Ruiner CE; Handrick R; Eibl HJ; Belka C; Jendrossek V
    Radiat Oncol; 2010 Nov; 5():108. PubMed ID: 21080918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of treatment volumes and techniques in prostate cancer radiation therapy.
    Lee CT; Dong L; Ahamad AW; Choi H; Cheung R; Lee AK; Horne DF; Breaux AJ; Kuban DA
    Am J Clin Oncol; 2005 Dec; 28(6):618-25. PubMed ID: 16317275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.
    Kortenhorst MS; Wissing MD; Rodríguez R; Kachhap SK; Jans JJ; Van der Groep P; Verheul HM; Gupta A; Aiyetan PO; van der Wall E; Carducci MA; Van Diest PJ; Marchionni L
    Epigenetics; 2013 Sep; 8(9):907-20. PubMed ID: 23880963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Options of hypofractionation of proton boost in locally advanced prostate cancer].
    Khmelevskiĭ EV; Pan'shin GA; Kancheli IN; Khoroshkov VS
    Vopr Onkol; 2012; 58(6):787-94. PubMed ID: 23600305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
    Incrocci L; Wortel RC; Alemayehu WG; Aluwini S; Schimmel E; Krol S; van der Toorn PP; Jager H; Heemsbergen W; Heijmen B; Pos F
    Lancet Oncol; 2016 Aug; 17(8):1061-1069. PubMed ID: 27339116
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A cell-based high-throughput screening assay for radiation susceptibility using automated cell counting.
    Hodzic J; Dingjan I; Maas MJ; van der Meulen-Muileman IH; de Menezes RX; Heukelom S; Verheij M; Gerritsen WR; Geldof AA; van Triest B; van Beusechem VW
    Radiat Oncol; 2015 Feb; 10():55. PubMed ID: 25888875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase 1 Trial of Everolimus and Radiation Therapy for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy.
    Narayan V; Vapiwala N; Mick R; Subramanian P; Christodouleas JP; Bekelman JE; Deville C; Rajendran R; Haas NB
    Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):355-361. PubMed ID: 27986349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin.
    Zellweger T; Chi K; Miyake H; Adomat H; Kiyama S; Skov K; Gleave ME
    Clin Cancer Res; 2002 Oct; 8(10):3276-84. PubMed ID: 12374699
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term results of intensity-modulated radiotherapy with three dose-fractionation regimens for localized prostate cancer.
    Takemoto S; Shibamoto Y; Sugie C; Manabe Y; Yanagi T; Iwata H; Murai T; Ishikura S
    J Radiat Res; 2019 Mar; 60(2):221-227. PubMed ID: 30566649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation.
    Tsai MH; Cook JA; Chandramouli GV; DeGraff W; Yan H; Zhao S; Coleman CN; Mitchell JB; Chuang EY
    Cancer Res; 2007 Apr; 67(8):3845-52. PubMed ID: 17440099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
    Dearnaley D; Syndikus I; Mossop H; Khoo V; Birtle A; Bloomfield D; Graham J; Kirkbride P; Logue J; Malik Z; Money-Kyrle J; O'Sullivan JM; Panades M; Parker C; Patterson H; Scrase C; Staffurth J; Stockdale A; Tremlett J; Bidmead M; Mayles H; Naismith O; South C; Gao A; Cruickshank C; Hassan S; Pugh J; Griffin C; Hall E;
    Lancet Oncol; 2016 Aug; 17(8):1047-1060. PubMed ID: 27339115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis.
    Livsey JE; Cowan RA; Wylie JP; Swindell R; Read G; Khoo VS; Logue JP
    Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1254-9. PubMed ID: 14630259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carbon ion irradiation of the human prostate cancer cell line PC3: a whole genome microarray study.
    Suetens A; Moreels M; Quintens R; Chiriotti S; Tabury K; Michaux A; Grégoire V; Baatout S
    Int J Oncol; 2014 Apr; 44(4):1056-72. PubMed ID: 24504141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. mRNA Expression Profiles for Prostate Cancer following Fractionated Irradiation Are Influenced by p53 Status.
    Simone CB; John-Aryankalayil M; Palayoor ST; Makinde AY; Cerna D; Falduto MT; Magnuson SR; Coleman CN
    Transl Oncol; 2013; 6(5):573-85. PubMed ID: 24151538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.